You are here

  • Home
  • Archive
  • Volume 11, Issue 2
  • The 5 component acellular pertussis vaccine combined with tetanus and diphtheria toxoids was efficacious in adolescents and adults

Article Text

Article menu
Download PDFPDF
Therapeutics
The 5 component acellular pertussis vaccine combined with tetanus and diphtheria toxoids was efficacious in adolescents and adults

https://doi.org/10.1136/ebm.11.2.51

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 2005;293:3003–11.
    OpenUrlCrossRefPubMedWeb of Science

    
 
 Q In adolescents and adults, is a 5 component acellular pertussis vaccine combined with tetanus and diphtheria toxoids (Tdap) as immunogenic and as safe as the licensed tetanus and diphtheria toxoid (Td) vaccine?

    Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Internal medicine ★★★★★☆☆ Infectious disease ★★★★★★☆

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    concealed.

    Embedded ImageBlinding:

    blinded (patients, healthcare providers, outcome assessors, and laboratory personnel).

    Embedded ImageFollow up period:

    28 days for immunogenicity and 6 months for safety.

    Embedded ImageSetting:

    39 clinical centres in the US.

    Embedded ImageParticipants:

    4480 healthy adolescents and adults with body temperature <38.0°C. Exclusion criteria included receipt of any pertussis, diphtheria, or tetanus containing vaccines in the past 5 years; diagnosis of pertussis within 2 years; allergy or sensitivity …

    View Full Text

    Footnotes

    • * See glossary.

    • For correspondence: Dr M E Pichichero, University of Rochester Medical Center, Rochester, NY,USA. michael_pichichero{at}urmc.rochester.edu

    • Source of funding: Sanofi Pasteur.

    Linked Articles

    • Glossary
      Glossary
      BMJ Publishing Group Ltd
      BMJ Evidence-Based Medicine 2006; 11 63a-63a Published Online First: 30 Mar 2006. doi: 10.1136/ebm.11.2.63a